WO2019153203A1 - 氧杂螺环双膦配体的合成与应用 - Google Patents

氧杂螺环双膦配体的合成与应用 Download PDF

Info

Publication number
WO2019153203A1
WO2019153203A1 PCT/CN2018/075860 CN2018075860W WO2019153203A1 WO 2019153203 A1 WO2019153203 A1 WO 2019153203A1 CN 2018075860 W CN2018075860 W CN 2018075860W WO 2019153203 A1 WO2019153203 A1 WO 2019153203A1
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
group
ligand
cdcl
mmol
Prior art date
Application number
PCT/CN2018/075860
Other languages
English (en)
French (fr)
Inventor
张绪穆
陈根强
黄佳明
Original Assignee
凯特立斯（深圳）科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 凯特立斯（深圳）科技有限公司 filed Critical 凯特立斯（深圳）科技有限公司
Priority to PCT/CN2018/075860 priority Critical patent/WO2019153203A1/zh
Priority to EP18904663.4A priority patent/EP3730502B1/en
Priority to US16/770,087 priority patent/US11299507B2/en
Publication of WO2019153203A1 publication Critical patent/WO2019153203A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
    • B01J31/2208—Oxygen, e.g. acetylacetonates
    • B01J31/2213—At least two complexing oxygen atoms present in an at least bidentate or bridging ligand
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • B01J31/249—Spiro-condensed ring systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
    • B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/36—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/60—Reduction reactions, e.g. hydrogenation
    • B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
    • B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
    • B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the present invention relates to the synthesis of a novel oxaspirocyclobisphosphine ligand.
  • the compound can be used as a chiral ligand in asymmetric catalytic reaction, and has high potential application value in the field of asymmetric catalysis, and belongs to the field of asymmetric catalysis.
  • the bisphosphine ligand is one of the most widely used ligands studied to date. It exhibits excellent activity and reactivity in asymmetric hydrogenation, asymmetric hydroformylation, asymmetric Pauson-Khand reaction, asymmetric Heck reaction, asymmetric cycloaddition reaction, asymmetric cyclic isomerization reaction, etc. Reflection selectivity.
  • the DIOP synthesized by the Kagan group, the BINAP developed by the Noyori group, and the DIPAMP ligand developed by the Knowles group are milestones in the history of the development of bisphosphine ligands. They are widely used in academia and industry. A variety of chiral bisphosphine ligands are then synthesized, such as SegePhos, DifluoPhos, SynPhos, Cn- TunePhos, TangPhos, DuanPhos, ZhangPhos, SKP, SDP, SFDP, and the like.
  • the present invention provides an oxaspirocyclophosphorus ligand having the structure of the following general formula (I):
  • R 1 and R 2 are independently an alkyl group, an alkoxy group, an aryl group, an aryloxy group or a hydrogen atom, and R 1 , R 2 , R 3 and R 4 may be cyclic or uncyclic; and R 5 and R 6 are independently an alkane. a group, an aryl group or a hydrogen atom; R 7 and R 8 are an alkyl group, a benzyl group or an aryl group.
  • the above alkyl group is preferably methyl, ethyl, propyl, butyl or the like;
  • the alkoxy group is preferably a methoxy group, an ethoxy group, a propoxy group, a butoxy group or the like;
  • the aryl group is preferably a phenyl group or the like which is substituted or unsubstituted with an alkyl group or an alkoxy group, and the alkyl group and the alkoxy group are as defined above.
  • the aryloxy group is preferably a methoxyphenyl group, an ethoxyphenyl group or the like.
  • a further preferred embodiment is that R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are simultaneously hydrogen.
  • the oxaspirobisphosphine ligand is a ( ⁇ )-oxaspirobiphosphine ligand, a (+)-oxaspirobiphosphine ligand, or a (-)-oxaspirobisphosphine ligand.
  • Ar is preferably an alkyl group, a benzyl group or an aryl group; and most preferably, Ar is a phenyl group substituted by a phenyl group, an alkyl group or an alkoxy group.
  • an alkyl group and an alkoxy group are as defined above.
  • Another object of the present invention is to provide a method for synthesizing the aforementioned compound, which is synthesized by the following route:
  • Another object of the present invention is to provide the use of the compound in catalytic asymmetric reaction comprising: hydrogenation reaction, hydroformylation reaction, hydrosilylation reaction, hydroboration reaction, hydrogen hydroxylation reaction, hydrogen ammonia Chemical reaction, hydrocyanation reaction, isomerization formylation reaction, hydrogen ammonia methylation reaction, transfer hydrogenation reaction, allylation reaction, olefin metathesis reaction, cycloisomerization reaction, Diels-Alder reaction, Symmetric coupling reaction, Aldol reaction, Michael addition reaction, asymmetric epoxidation, kinetic resolution and [m+n] cyclization.
  • the bisphosphonium ruthenate complex prepared by the compound has high activity and enantioselectivity to hydrogenation of an unsaturated carboxylic acid in an organic solvent, and is more than 99%.
  • the bisphosphonium ruthenate complex is a compound of the formula:
  • R alkyl, fluoroalkyl or aryl; preferably alkyl and aryl are as defined above.
  • a preferred catalytic asymmetric reaction comprises: using the aforementioned compound as a catalyst, and the reaction route is as follows:
  • R alkyl, fluoroalkyl or aryl; preferably alkyl and aryl are as defined above.
  • Another object of the present invention is to provide a bisphosphonium ruthenate complex having high activity and enantioselectivity for hydrogenation of an unsaturated carboxylic acid in an organic solvent, the bisphosphonate complex being Compound:
  • R alkyl, fluoroalkyl or aryl; preferably alkyl and aryl are as defined above.
  • the oxaspirocyclic compound has a central chirality, and thus has a levo-oxaspiro-bisphosphine ligand and a dextro-oxaspiro-bisphosphine ligand, and the racemic spiro bisphosphine ligand can pass racemization
  • the oxaspirocyclophenol is synthesized as a raw material.
  • the present invention can be used as a chiral ligand in the asymmetric hydrogenation of an unsaturated carboxylic acid. Its complex with ruthenium can give an enantioselectivity of greater than 99% in the asymmetric hydrogenation of methyl-cinnamic acid.
  • Figure 1 Schematic diagram of the preparation of various chiral compounds of the invention, and corresponding conversion and enantioselective ee values.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

公开了一种氧杂螺环双膦配体的合成与应用，该双膦配体从氧杂螺环二酚出发经过三氟甲磺酰化、钯催化二芳基氧膦偶联、三氯硅氢还原、再次钯催化二芳基氧膦偶联和再次的三氯硅氢还原制备得到。该氧杂螺环化合物具有中心手性，作为手性配体用于不饱和羟酸的不对称氢化中，其中与钌的络合物在甲基-肉桂酸的不对称氢化中可以得到大于99%的对映选择性。

Description

氧杂螺环双膦配体的合成与应用 技术领域
本发明涉及一种新型氧杂螺环双膦配体的合成。该化合物可以作为手性配体应用于不对称催化反应中，在不对称催化领域具有很高的潜在应用价值，属于不对称催化领域。
背景技术
在过去的几十年间，不对称催化得到了飞速的发展，各种各样的手性配体被合成出来，并应用到不对称催化领域当中。在众多的手性配体当中双膦配体是到目前为止研究的最多应用的最广的配体之一。它在不对称氢化、不对称氢甲酰化反应、不对称Pauson-Khand反应、不对称Heck反应、不对称环加成反应、不对称环异构化反应等反应中表现出优异的活性和对映选择性。
Kagan小组合成的DIOP、Noyori小组发展的BINAP以及Knowles小组发展的DIPAMP配体在双膦配体的发展历史中具有里程碑意义。它们在学术界和工业界得到了非常广泛的应用。随后各种各样的手性双膦配体被合成出来，例如SegePhos、DifluoPhos、SynPhos、C n-TunePhos、TangPhos、DuanPhos、ZhangPhos、SKP、SDP、SFDP等。
尽管现在手性双膦配体不管在种类上还是在数目上都已经非常丰富，但是每一种配体都有它独特的性质，因此，开发新型的手性双膦配体具有非常重要的意义。
发明内容
鉴于现有技术需要改善的问题，本发明提供了一种氧杂螺环双磷配体，具有以下通式(I)的结构：
Figure PCTCN2018075860-appb-000001
通式(I)中：
R 1、R 2独立为烷基、烷氧基、芳基、芳氧基或者氢原子，R 1、R 2、R 3和R 4可成环或不成环；R 5、R 6独立为烷基、芳基或者氢原子；R 7、R 8为烷基、苄基或者芳基。
上述术语烷基优选为甲基、乙基、丙基、丁基等；
烷氧基优选为甲氧基、乙氧基、丙氧基、丁氧基等；
芳基优选为被烷基或者烷氧基取代或者未取代的苯基等，烷基和烷氧基如上定义。
芳氧基优选为甲氧苯基、乙氧苯基等。
进一步的优选方案为R 1、R 2、R 3、R 4、R 5和R 6同时为氢。
所述氧杂螺环双磷配体是(±)-氧杂螺环双膦配体，(+)-氧杂螺环双膦配体，或(-)-氧杂螺环双膦配体。
进一步的优选方案为所述氧杂螺环双磷配体是下式化合物：
Figure PCTCN2018075860-appb-000002
其中优选Ar为烷基、苄基或者芳基；最优选Ar为苯基、烷基或者烷氧基取代的苯基。
其中，烷基和烷氧基如上定义。
本发明另一目的在于提供一种合成前述化合物的方法，通过以下的路线合成得到：
Figure PCTCN2018075860-appb-000003
本发明另一目的在于提供所述化合物在催化不对称反应中的应用，所述不对称反应包括：氢化反应，氢甲酰化反应，硅氢化反应，硼氢化反应，氢羟基化反应，氢氨化反应，氢氰基化反应，异构化甲酰基化反应，氢氨甲基化反应，转移氢化反应，烯丙基化反应，烯烃复分解反应，环异构化反应，Diels-Alder反应，不对称偶联反应，Aldol反应，Michael加成反应，不对称环氧化反应，动力学拆分和[m+n]环化反应。
该化合物制成的双膦醋酸钌络合物在有机溶剂中对不饱和羧酸的氢化具有很高的活性和对映选择性，大于99％。
所述双膦醋酸钌络合物是下式化合物：
Figure PCTCN2018075860-appb-000004
其中，R＝烷基，氟代烷基或芳基；优选烷基和芳基如上定义。
具体的，优选的一种催化不对称反应，包括：使用前述的化合物作为催化剂，反应路线如下：
Figure PCTCN2018075860-appb-000005
其中，R＝烷基，氟代烷基或芳基；优选烷基和芳基如上定义。
本发明另一目的提供了一种双膦醋酸钌络合物，在有机溶剂中对不饱和羧酸的氢化具有很高的活性和对映选择性，所述双膦醋酸钌络合物是下式化合物：
Figure PCTCN2018075860-appb-000006
其中，R＝烷基，氟代烷基或芳基；优选烷基和芳基如上定义。
本发明相对于现有技术的有益效果包括：
(1)该氧杂螺环化合物具有中心手性，因此有左旋氧杂螺环双膦配体和右旋氧杂螺环双膦配体，消旋的螺环双膦配体可以通过消旋的氧杂螺环二酚为原料合成得到。
(2)本发明可以作为手性配体用于不饱和羧酸的不对称氢化中。其与钌的络合物在甲基-肉桂酸的不对称氢化中可以得到大于99％的对映选择性。
附图说明
图1，本发明多种不同手性化合物的制备示意图，以及对应的转化率和对映选择性ee值。
具体实施方式
下面通过实施例和附图对本发明加以说明，但本发明并不仅限于以下实施例。
实施例1：
(R)-2-氢,2'-氢-3,3'-螺二[苯并呋喃]-4,4'-二三氟甲磺酸酯2的合成：
Figure PCTCN2018075860-appb-000007
N 2氛围下，向一个250mL反应瓶中加入(S)-6(7.68g,30mmol)，然后加入150mL干燥的二氯甲烷。室温下搅拌体下加入吡啶(6.0mL,100mmol)。待反应体系澄清后，冷却至零度，然后逐滴加入Tf 2O(12.0mL,70mmol)，滴加完毕后升至室温继续搅拌1h。加水淬灭反应。反应体系用稀盐酸洗涤，有机相在减压条件下出去溶剂，经过柱层析就可以得到产物(S)-7(15.6g,产率:99％)
白色固体. 1HNMR(500MHz,CDCl 3)δ4.70(d,J＝10.0Hz,2H,CH 2),4.87-4.90(m,2H,CH 2),6.91-6.93(m,4H,Ar),7.32(dd,J 1＝8.5Hz,J 2＝8.0Hz,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ162.3,145.8,131.9,119.8,118.1(q,J＝320.0Hz,CF 3),113.1,110.4,82.5,54.9. 19C{1H}NMR(126MHz,CDCl 3)δ-74.23.HRMS(ESI)calcd.for C 171H 1F 6O 8S 2[M+H] +:520.9800,Found:520.9794,[α] 20 D＝+19.2(c＝0.5,丙酮).
实施例2：
(R)-4'-(二苯基膦氧基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯3a的合成：
Figure PCTCN2018075860-appb-000008
N 2氛围下，反应瓶中加入2(5.2g,10mmol)、dppb(213mg,0.05mmol)、Ph 2POH(3.87g,15mmol)、Pd(PAc) 2(112mg,0.05mmol)和DIPEA(6.5mL,40mmol)，最后加入50mL无水无氧的DMSO。100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物3a(5.15g,产率＝90％)。
白色固体. 1HNMR(400MHz,CDCl 3)δ4.64-4.68(m,2H,CH 2),4.77(d,J＝9.6Hz,1H,CH 2),5.15-5.18(m,1H,CH 2),6.40(d,J＝8.0Hz,1H,Ar),6.58-6.60(m,1H,Ar),6.78-6.80(m,1H,Ar),6.88-6.90(m,1H,Ar),6.94-6.98(m,2H,Ar),7.05-7.13(m,3H,Ar),7.16-7.20(m,2H,Ar),7.24-7.28(m,4H,Ar). 13C{1H}NMR(101MHz,CDCl 3)δ162.6,160.3,145.4,136.6,134.5,133.4(m),132.3,132.0,131.2,130.0,128.4(m),122.6(m),120.7,112.3,110.9,109.4,84.5,82.9,56.3,26.9. 31P{1H}NMR(202MHz,CDCl 3)δ21.95(s).HRMS(ESI)calcd.for C 18H 21O 6F 3PS[M+H] +:573.0749,Found:573.0743,[α] 20 D＝+237.2(c＝0.5,丙酮).
实施例3：
(R)-4'-(二苯基膦基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯4a的合成：
Figure PCTCN2018075860-appb-000009
100mL封管中，加入3a(2.86g,5mmol)、DIPEA(6.6mL,40mmol)、20mL和三氯硅氢(2.0mL,20mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体4a(2.5g,产率＝90％)。
白色固体. 1HNMR(400MHz,CDCl 3)δ4.58-4.62(m,2H,CH 2),4.69-4.72(m,1H,CH 2),5.08-5.12(m,1H,CH 2),6.32-6.34(m,1H,Ar),6.51-6.52(m,1H,Ar),6.72-6.74(m,1H,Ar),6.81-6.85(m,1H,Ar),6.88-6.91(m,2H,Ar),6.99-7.05(m,3H,Ar),7.10-7.13(m,2H,Ar),7.14-7.22(m,4H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ162.6,160.3,145.4,136.6,134.5(m),133.5(m),132.0,131.3,130.1,128.8(m),127.8,122.6,112.3,110.9,109.5,84.5,83.0,56.3. 31P{1H}NMR(202MHz,CDCl 3)δ-22.32(s).HRMS(ESI)calcd.for C 18H 21O 5F 3PS[M+H] +:557.0799,Found:557.0794,[α] 20 D＝+56.0(c＝0.5,丙酮).
实施例4：
(R)-(4'-(二苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]-4-二苯基膦氧5a的合成：
Figure PCTCN2018075860-appb-000010
N 2氛围下，反应瓶中加入4a(2.78g,5mmol)、dppb(107mg,0.025mmol)、Ph 2POH(1.94g,7.5mmol)、Pd(PAc) 2(56mg,0.0025mmol)和DIPEA(3.2mL,20mmol)，最后加入20mL无水无氧的DMSO。100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物5a(2.66g,产率＝87％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ4.38(d,J＝9.5Hz,1H,CH 2),4.43(d,J＝9.0Hz,1H,CH 2),4.46(d,J＝9.5Hz,1H,CH 2),5.19(d,J＝9.0Hz,1H,CH 2),6.56-6.59(m,1H,Ar),6.74-6.84(m,4H,Ar),7.01-7.03(m,1H,Ar),7.07-7.12(m,3H,Ar),7.17-7.30(m,6H,Ar),7.32-7.36(m,5H,Ar),7.38-7.43(m,3H,Ar),7.48-7.55(m,3H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ162.9,160.4,138.1,137.9,137.4,134.9,134.4(m),134.1(m),133.3(m),132.5,132.1,131.7(m),129.8,128.9(m),128.4(m),128.1(m),126.7(m),113.4,110.2,85.2,84.0,58.2(m). 31P{1H}NMR(162MHz,CDCl 3)δ29.41(s),-20.96(s).HRMS(ESI)calcd.for C 39H 31O 3P 2[M+H] +:609.1748,Found:609.1743,[α] 20 D＝+224.0(c＝0.5,丙酮).
实施例5：
(R)-4,4'-二(二苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]6a的合成：
Figure PCTCN2018075860-appb-000011
100mL封管中，加入3a(1.216g,2mmol)、DIPEA(3.3mL,20mmol)、10mL甲苯和三氯硅氢(1.0mL,10mmol)。反应在120℃条件下搅拌过夜。反应体系用 过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体6a(1.15g,产率＝96％)。
白色固体. 1HNMR(500MHz,CDCl 3)4.38(d,J＝9.5Hz,2H,CH 2),4.49(d,J＝9.5Hz,2H,CH 2),6.67-6.68(m,2H,Ar),6.85-6.86(m,2H,Ar),6.92(s,4H,Ar),7.01-7.03(m,1H,Ar),7.11-7.23(m,12H,Ar),7.29-7.30(m,6H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ160.8(t,J＝7.5Hz),137.1,136.8,135.0,134.1,133.4,129.5,128.7128.4,128.0,127.3,110.4,83.6,58.0(m). 31P{1H}NMR(162MHz,CDCl 3)δ-20.99(s).HRMS(ESI)calcd.for C 39H 31O 2P 2[M+H] +:593.1799,Found:593.1782,[α] 20 D＝+246(c＝0.5,丙酮).
实施例6：
(R)-4'-(二对甲基苯基膦氧基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯3b的合成：
Figure PCTCN2018075860-appb-000012
N 2氛围下，反应瓶中加入2(2.6g,5mmol)、dppb(107mg,0.025mmol)、Ar 2POH(1.73g,7.5mmol)、Pd(PAc) 2(56mg,0.025mmol)和DIPEA(3.2mL,20mmol)，最后加入30mL无水无氧的DMSO。100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物3b(2.60g,产率＝87％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ2.36(s,3H,CH 3),2.38(s,3H,CH 3),4.60-4.62(m,1H,CH 2),4.70-4.74(m,2H,CH 2),5.69(d,J＝8.5Hz,1H,CH 2),6.17(d,J＝8.0Hz,1H,Ar),6.66-6.70(m,1H,Ar),6.80-6.81(m,1H,Ar),7.03-7.07(m,2H,Ar),7.10-7.16(m,4H,Ar),7.18-7.21(m,3H,Ar),7.36-7.40(m,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ163.8,161.9,144.7,142.0(m),131.9(m),131.5(m),131.2(m),130.7(m),130.2,130.0,129.3,129.0(m),128.1,126.9,123.5,121.8, 119.8,116.6,113.8,111.7,109.3,85.6,83.6,56.5,21.5. 31P{1H}NMR(202MHz,CDCl 3)δ29.86(s).HRMS(ESI)calcd.for C 30H 25O 6F 3PS[M+H] +:601.1062,Found:601.1056,[α] 20 D＝+108.4(c＝0.5,丙酮).
实施例7：
(R)-4'-(二对甲基苯基膦基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯4b的合成：
Figure PCTCN2018075860-appb-000013
100mL封管中，加入3b(3.00g,5mmol)、DIPEA(3.2mL,20mmol)、20mL甲苯和三氯硅氢(2.0mL,20mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体4b(2.70g,产率＝92％)。
白色固体. 1HNMR(400MHz,CDCl 3)δ4.58-4.62(m,2H,CH 2),4.69-4.72(m,1H,CH 2),5.08-5.12(m,1H,CH 2),6.43(d,J＝9.0Hz,1H,Ar),6.51-6.52(m,1H,Ar),6.72-6.74(m,1H,Ar),6.81-6.85(m,1H,Ar),6.88-6.91(m,2H,Ar),6.99-7.05(m,3H,Ar),7.10-7.13(m,2H,Ar),7.14-7.22(m,4H,Ar). 13C{1H}NMR(101MHz,CDCl 3)δ162.7,160.2,153.6,145.5,138.6,133.7,133.5,131.1,129.9,129.3,129.0,127.6,122.6,112.3,110.7,109.4,84.3,82.9,56.3,26.9,21.2. 31P{1H}NMR(202MHz,CDCl 3)δ-22.32(s).HRMS(ESI)calcd.for C 30H 25O 5F 3PS[M+H] +:585.1112,Found:585.1107,[α] 20 D＝+111.4(c＝0.5,丙酮).
实施例8：
(R)-(4'-(二对甲基苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]-4-二苯基膦氧5b的合成：
Figure PCTCN2018075860-appb-000014
N 2氛围下，反应瓶中加入4b(0.584g,2mmol)、dppb(43mg,0.1mmol)、Ph 2POH(0.69g,3mmol)、Pd(PAc) 2(22.4mg,0.1mmol)和DIPEA(0.50mL,4mmol)，最后加入20mL无水无氧的DMSO。100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物5b(1.12g,产率＝85％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ2.27(s,3H,CH 3),2.31(s,6H,CH 3),2.35(s,3H,CH 3)4.36(d,J＝9.0Hz,1H,CH 2),4.44(t,J＝9.5Hz,2H,CH 2),5.25(d,J＝9.0Hz,1H,CH 2),6.56-6.58(m,1H,Ar),6.67-6.70(m,2H,Ar),6.74-6.78(m,1H,Ar),6.79-6.80(m,1H,Ar),6.89-6.91(m,2H,Ar),6.97-7.00(m,3H,Ar),7.04-7.12(m,5H,Ar),7.18-7.26(m,5H,Ar),7.37-7.42(m,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ171.0,162.8,160.2,141.7,141.5,138.5,137.8,137.6,137.3,134.0(m),133.2,132.1,131.7,131.2,130.0,129.2(m),128.7(m),126.4,113.0,109.9,85.0,84.0,60.3,58.1(m),21.5,21.2. 31P{1H}NMR(202MHz,CDCl 3)δ29.37(s),-22.71(s).HRMS(ESI)calcd.for C 43H 39O 3P 2[M+H] +:665.2374,Found:665.2369,[α] 20 D＝+211.2(c＝0.5,丙酮).
实施例9：
(R)-4,4'-二(二对甲基苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]6b的合成：
Figure PCTCN2018075860-appb-000015
100mL封管中，加入5b(0.664g,1mmol)、DIPEA(3.3mL,20mmol)、10mL甲苯和三氯硅氢(1.0mL,10mmol)。反应在120℃条件下搅拌过夜。反应体系用 过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体6b(0.62g,产率＝95％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ2.29(s,6H,CH 3),2.33(s,6H,CH 3),4.35(d,J＝9.5Hz,2H,CH 2),4.44(d,J＝9.0Hz,2H,CH 2),6.66-6.68(m,2H,Ar),6.81-6.84(m,6H,Ar),6.93-6.95(m,4H,Ar),7.10(s,8H,Ar),7.14-7.17(m,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ160.8(m),138.6,137.7,135.8,134.8(m),134.2(m),133.5(m),129.2(m),128.8(m),110.1,83.6(m),58.0(m),21.3. 31P{1H}NMR(202MHz,CDCl 3)δ-22.82(s).HRMS(ESI)calcd.for C 43H 39O 2P 2[M+H] +:649.2425,Found:649.2420,[α] 20 D＝+231.2(c＝0.5,丙酮).
实施例10：
(R)-4'-(二对甲氧基苯基膦氧基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯3c的合成：
Figure PCTCN2018075860-appb-000016
N 2氛围下，反应瓶中加入2(5.2g,10mmol)、dppb(213mg,0.05mmol)、Ar 2POH(3.93g,15mmol)、Pd(PAc) 2(112mg,0.05mmol)和DIPEA(6.5mL,40mmol)，最后加入50mL无水无氧的DMSO。100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物3c(5.78g,产率＝91％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ3.81(s,3H,CH 3),3.84(s,3H,CH 3),4.62(d,J＝9.5Hz,1H,CH 2),4.70-4.75(m,2H,CH 2),5.71(d,J＝8.5Hz,1H,CH 2),6.23(d,J＝8.5Hz,1H,CH 2),6.65-6.70(m,1H,Ar),6.80-6.82(m,3H,Ar),6.88-6.91(m,2H,Ar),7.03-7.07(m,2H,Ar),7.16-7.27(m,3H,Ar),7.39-7.43(m,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ163.8,162.2(m),144.7,133.7,133.0,131.4(m),130.3(m),129.3,126.9,125.9,125.0,122.8,121.7(m),119.1,116.6,113.8(m), 111.5,109.2,85.6,83.6,56.5,55.2. 31P{1H}NMR(202MHz,CDCl 3)δ29.39(s).HRMS(ESI)calcd.for C 30H 25O 8F 3PS[M+H] +:633.0960,Found:633.0954,[α] 20 D＝+62.4(c＝0.5,丙酮).
实施例11：
(R)-4'-(二对甲氧基苯基膦基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯4c的合成：
Figure PCTCN2018075860-appb-000017
100mL封管中，加入3c(2.86g,5mmol)、DIPEA(6.6mL,40mmol)、20mL和三氯硅氢(2.0mL,20mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体4c(2.81g,产率＝91％)。
白色固体. 1HNMR(400MHz,CDCl 3)δ4.58-4.62(m,2H,CH 2),4.69-4.72(m,1H,CH 2),5.08-5.12(m,1H,CH 2),6.43(d,J＝9.0Hz,1H,Ar),6.51-6.52(m,1H,Ar),6.72-6.74(m,1H,Ar),6.81-6.85(m,1H,Ar),6.88-6.91(m,2H,Ar),6.99-7.05(m,3H,Ar),7.10-7.13(m,2H,Ar),7.14-7.22(m,4H,Ar). 13C{1H}NMR(101MHz,CDCl 3)δ162.7,160.2,153.6,145.5,138.6,133.7,133.5,131.1,129.9,129.3,129.0,127.6,122.6,112.3,110.7,109.4,84.3,82.9,56.3,26.9,21.2. 31P{1H}NMR(202MHz,CDCl 3)δ-22.32(s).HRMS(ESI)calcd.for C 30H 25O 5F 3PS[M+H] +:585.1112,Found:585.1107,[α] 20 D＝+111.4(c＝0.5,丙酮).
实施例12：
(R)-(4'-(二对甲氧基苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]-4-二苯基膦氧5c的合成：
Figure PCTCN2018075860-appb-000018
N 2氛围下，反应瓶中加入4c(1.232g,2mmol)、dppb(43mg,0.1mmol)、Ph 2POH(0.79g,3mmol)、Pd(PAc) 2(22.4mg,0.1mmol)和DIPEA(1.6mL,5mmol)，最后加入20mL无水无氧的DMSO，100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物5c(1.27g,产率＝87％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ3.73(s,3H,CH 3),3.74(s,3H,CH 3),3.77(s,6H,CH 3),3.80(s,3H,CH 3)4.37(d,J＝9.0Hz,1H,CH 2),4.45-4.47(m,2H,CH 2),5.28(d,J＝9.0Hz,1H,CH 2),6.55-6.57(m,1H,Ar),6.64-6.71(m,6H,Ar),6.75-6.83(m,4H,Ar),6.89-6.91(m,2H,Ar),6.98-7.00(m,1H,Ar),7.06-7.11(m,1H,Ar),7.13-7.14(m,2H,Ar),7.20-7.26(m,3H,Ar),7.42-7.45(m,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ171.0,162.8(m),161.9(m),160.3(m),137.5,135.4,134.8,134.0(m),133.5,130.6,129.9,128.5(m),128.1,126.6(m),126.0(m),124.7,123.8,113.9(m),112.9,109.8,85.0,84.2,60.3,58.1(m),55.0(m). 31P{1H}NMR(202MHz,CDCl 3)δ28.75(s),-24.27(s).HRMS(ESI)calcd.for C 43H 39O 7P 2[M+H] +:729.2171,Found:729.2166,[α] 20 D＝+173.2(c＝0.5,丙酮).
实施例13：
(R)-4,4'-二(二对甲基苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]6c的合成：
Figure PCTCN2018075860-appb-000019
100mL封管中，加入5c(0.728g,1mmol)、DIPEA(1.65mL,10mmol)、10mL 甲苯和三氯硅氢(1.0mL,10mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体6c(0.64g,产率＝90％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ3.75(s,6H,CH 3),3.79(s,6H,CH 3),4.36(d,J＝9.0Hz,2H,CH 2),4.46(d,J＝9.5Hz,2H,CH 2),6.64-6.70(m,6H,Ar),6.82-6.85(m,10H,Ar),7.12-7.18(m,6H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ160.8(m),160.1(m),136.2(m),135.5(m),134.5(m),129.3,128.3(m),126.8,114.0(m),110.0,83.6(m),57.9(m),55.1(m). 31P{1H}NMR(202MHz,CDCl 3)δ-24.20(s).HRMS(ESI)calcd.for C 43H 39O 2P 2[M+H] +:649.2425,Found:649.2420,[α] 20 D＝+133.6(c＝0.5,丙酮).
实施例14：
(R)-4'-(二3,5-二甲基苯基膦氧基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯3d的合成：
Figure PCTCN2018075860-appb-000020
N 2氛围下，反应瓶中加入2(5.20g,10mmol)、dppb(213mg,0.05mmol)、Ar 2POH(3.87g,15mmol)、Pd(PAc) 2(112mg,0.05mmol)和DIPEA(6.5mL,40mmol)，最后加入50mL无水无氧的DMSO，100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物3d(5.15g,产率＝82％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ2.15(s,6H,CH 3),2.17(s,6H,CH 3),4.54(d,J＝9.5Hz,1H,CH 2),4.62-4.64(m,2H,CH 2),5.69(d,J＝8.5Hz,1H,CH 2),6.07(d,J＝8.0Hz,1H,Ar),6.63-6.67(m,1H,Ar),6.72-6.78(m,3H,Ar),6.93-6.98(m,2H,Ar),7.00-7.05(m,4H,Ar),7.12-7.18(m,1H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ163.9,161.7,144.7,137.8(m),133.9,133.3(m),131.5,130.7,130.0(m), 129.4(m),128.7,126.9,121.6,119.1,116.5,113.6,111.3,109.1,85.7,83.6,56.3,21.2. 31P{1H}NMR(202MHz,CDCl 3)δ29.59(s).HRMS(ESI)calcd.for C 32H 29O 6F 3PS[M+H] +:629.1375,Found:629.1369,[α] 20 D＝+196.4(c＝0.5,丙酮).
实施例15：
(R)-4'-(二3,5-二甲基苯基膦基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯4d的合成：
Figure PCTCN2018075860-appb-000021
100mL封管中，加入3d(3.14g,5mmol)、DIPEA(6.6mL,40mmol)、20mL和三氯硅氢(2.0mL,20mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体4d(2.88g,产率＝94％)。
白色固体. 1HNMR(400MHz,CDCl 3)δ2.16(s,6H,CH 3),2.19(s,6H,CH 3),4.44(d,J＝9.0Hz,1H,CH 2),4.63-4.67(m,2H,CH 2),5.15-5.18(m,1H,CH 2),6.36-6.40(m,1H,Ar),6.51-6.53(m,3H,Ar),6.65-6.68(m,1H,Ar),6.73-6.79(m,3H,Ar),6.83-6.87(m,3H,Ar),6.99-7.01(m,1H,Ar),7.11-7.15(m,1H,Ar). 13C{1H}NMR(101MHz,CDCl 3)δ162.6,160.2,145.3,137.7(m),136.3,135.2,134.0,131.8(m),130.5(m),129.9,127.7,122.8,119.3,116.7,112.1,110.6,109.4,84.4,83.0,56.2,21.3. 31P{1H}NMR(162MHz,CDCl 3)δ-21.56(s).HRMS(ESI)calcd.for C 32H 29O 5F 3PS[M+H] +:613.1425,Found:613.1420,[α] 20 D＝+60.0(c＝0.5,丙酮).
实施例16：
(R)-(4'-(二3,5-二甲基苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]-4-二苯基膦氧5b的合成：
Figure PCTCN2018075860-appb-000022
N 2氛围下，反应瓶中加入4d(1.22g,2mmol)、dppb(107mg,0.1mmol)、Ph 2POH(0.77g,3mmol)、Pd(PAc) 2(22.4mg,0.1mmol)和DIPEA(0.8mL,5mmol)，最后加入10mL无水无氧的DMSO，100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物5d(1.22g,产率＝86％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ2.04(s,6H,CH 3),2.06(s,6H,CH 3),2.24(s,6H,CH 3),2.29(s,6H,CH 3),4.14(d,J＝9.5Hz,1H,CH 2),4.41(d,J＝9.5Hz,2H,CH 2),5.15(d,J＝8.5Hz,1H,CH 2),6.49(d,J＝7.5Hz,1H,Ar),6.70-6.73(m,1H,Ar),6.75-6.78(m,2H,Ar),6.86-6.90(m,3H,Ar),6.95-6.98(m,3H,Ar),7.03-7.06(m,2H,Ar),7.07(s,1H,Ar),7.09(s,1H,Ar),7.19(s,1H,Ar),7.21(s,1H,Ar),7.24-7.25(m,1H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ162.8(m),159.8(m),137.7(m),136.8(m),135.0,134.2,134.0.133.2(m),132.8,132.4(m),130.8(m),130.0(m),129.4(m),128.5(m),126.7,126.4,112.9,109.9,84.1,83.3,58.3(m),21.3(m). 31P{1H}NMR(202MHz,CDCl 3)δ-19.53(s),29.83(s).HRMS(ESI)calcd.for C 47H 47O 3P 2[M+H] +:721.3000,Found:721.2995,[α] 20 D＝+137.2(c＝0.5,丙酮).
实施例17：
(R)-4,4'-二(二3,5-二苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]6d的合成：
Figure PCTCN2018075860-appb-000023
100mL封管中，加入5d(0.72g,1mmol)、DIPEA(3.3mL,20mmol)、10mL 甲苯和三氯硅氢(1.0mL,10mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体6d(0.65g,产率＝93％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ2.07(s,6H,CH 3),2.09(s,6H,CH 3),2.24(s,6H,CH 3),2.26(s,6H,CH 3),4.19-4.20(m,2H,CH 2),4.31-4.34(m,2H,CH 2),6.65-6.66(m,4H,Ar),6.81-6.84(m,6H,Ar),6.85-6.88(m,4H,Ar),6.95-6.96(m,2H,Ar),7.18-7.22(m,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ160.9(m),137.7(m),137.2(m),136.1,133.8(m),132.3(m),131.0(m),129.6(m),127.1,110.1,82.9,58.3(m),21.3(m). 31P{1H}NMR(202MHz,CDCl 3)δ-19.92(s).HRMS(ESI)calcd.for C 47H 47O 2P 2[M+H] +:705.3051,Found:705.3046,[α] 20 D＝+138.0(c＝0.5,丙酮).
实施例18：
(R)-4'-(二3,5-二叔丁基基苯基膦氧基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯3e的合成：
Figure PCTCN2018075860-appb-000024
N 2氛围下，反应瓶中加入2(5.2g,10mmol)、dppb(213mg,0.05mmol)、Ar 2POH(6.39g,15mmol)、Pd(PAc) 2(112mg,0.05mmol)和DIPEA(6.5mL,40mmol)，最后加入50mL无水无氧的DMSO。100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物3e(7.43g,产率＝93％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ1.18(s,9H,CH 3),1.19(s,9H,CH 3),1.20(s,9H,CH 3),1.21(s,9H,CH 3),4.54-4.56(m,1H,CH 2),4.62-4.64(m,1H,CH 2),4.80-4.82(m,2H,CH 2),6.63-6.68(m,2H,Ar),6.82-6.88(m,6H,Ar),6.90-6.94(m,2H,Ar),7.15-7.21(m,1H,Ar),7.26-7.34(m,1H,Ar). 13C{1H}NMR(126MHz, CDCl 3)δ162.9,160.1,150.5,150.2,145.7,136.0(m),135.5,134.4,131.2,129.6,128.4,127.5,122.4(m),112.5,110.5,109.6,83.5,82.3,56.4(m),34.8(m),31.3(m). 31P{1H}NMR(202MHz,CDCl 3)δ-19.74(s).HRMS(ESI)calcd.for C 44H 53O 6F 3PS[M+H] +:797.3253,Found:797.3247,[α] 20 D＝+109.6(c＝0.5,丙酮).
实施例19：
(R)-4'-(二3,5-二叔丁基苯基膦基)-2氢,2'氢-3,3'-螺二[苯并呋喃]-4-三氟甲磺酸酯4e的合成：
Figure PCTCN2018075860-appb-000025
100mL封管中，加入3e(3.98g,5mmol)、DIPEA(6.6mL,40mmol)、20mL和三氯硅氢(2.0mL,20mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体4e(3.51g,产率＝90％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ1.17(s,9H,CH 3),1.19(s,9H,CH 3),1.20(s,9H,CH 3),1.21(s,9H,CH 3),4.52-4.55(m,1H,CH 2),4.60-4.63(m,1H,CH 2),4.77-4.82(m,2H,CH 2),6.61-6.69(m,2H,Ar),6.80-6.94(m,6H,Ar),7.14-7.22(m,2H,Ar),7.28-7.34(m,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ162.9,160.1(m),150.5(m),145.8,136.1(m),135.5(m),134.4,131.9(m),131.2,129.6,128.4(m),127.5,122.4(m),116.9,112.6,110.6,109.6,83.5,82.4,56.4(m),34.8(m),31.3(m). 31P{1H}NMR(202MHz,CDCl 3)δ-19.73(s).HRMS(ESI)calcd.for C 32H 29O 5F 3PS[M+H] +:781.3303,Found:781.3298,[α] 20 D＝+78.8(c＝0.5,丙酮).
实施例20：
(R)-(4'-(二3,5-二叔丁基苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]-4-二苯基膦氧5e的合成：
Figure PCTCN2018075860-appb-000026
N 2氛围下，反应瓶中加入4e(1.56g,2mmol)、dppb(43mg,0.1mmol)、Ph 2POH(1.28g,3mmol)、Pd(PAc) 2(22.4mg,0.1mmol)和DIPEA(1.6mL,10mmol)，最后加入10mL无水无氧的DMSO，100℃下反应6h。冷却至室温后，加入水淬灭反应，用乙酸乙酯萃取反应体系，有机相用无水硫酸钠干燥后减压条件下除去溶剂，经过简单的柱层析后就可以拿到产物5e(1.85g,产率＝92％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ1.95(s,18H,CH 3),1.02(s,18H,CH 3),1.27(s,18H,CH 3),1.30(s,18H,CH 3),3.78(d,J＝8.8Hz,1H,CH 2),4.36(d,J＝9.6Hz,1H,CH 2),4.45(d,J＝8.4Hz,1H,CH 2),4.91(d,J＝8.4Hz,1H,CH 2),6.67(d,J＝6.8Hz,2H,Ar),6.76-6.78(m,1H,Ar),6.86-6.90(m,2H,Ar),6.97-7.01(m,1H,Ar),7.06-7.10(m,2H,Ar),7.16-7.20(m,1H,Ar),7.22-7.24(m,2H,Ar),7.39(s,2H,Ar),7.41(s,2H,Ar),7.49(s,2H,Ar),7.61(d,J＝8.0Hz,2H,Ar),7.65(d,J＝9.6Hz,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ162.3,159.0,150.4(m),149.5(m),137.7,137.3(m),135.5(m),134.7,133.9(m),132.9,132.4(m),129.6(m),128.0(m),127.5,126.5(m),122.9,120.7,112.2,109.9,81.4,81.3,59.1,34.8(m),31.2(m). 31P{1H}NMR(202MHz,CDCl 3)δ30.86(s),-16.07(s).HRMS(ESI)calcd.for C 71H 95O 3P 2[M+H] +:1057.6756,Found:1057.6751,[α] 20 D＝+152.4(c＝0.5,丙酮).
实施例21：
(R)-4,4'-二(二3,5-二叔丁基苯基膦基)-2H,2'H-3,3'-螺二[苯并呋喃]6e的合成：
Figure PCTCN2018075860-appb-000027
100mL封管中，加入5e(1.01g,1mmol)、DIPEA(1.65mL,10mmol)、10mL甲苯和三氯硅氢(1.0mL,10mmol)。反应在120℃条件下搅拌过夜。反应体系用过量的碳酸氢钠饱和溶液淬灭，加入100mL乙酸乙酯，硅藻土过滤，有机相用无水硫酸钠干燥。减压下除去溶剂，然后柱层析得到白色固体6e(0.82g,产率＝79％)。
白色固体. 1HNMR(500MHz,CDCl 3)δ0.99(s,36H,CH 3),1.25(s,36H,CH 3),3.85(d,J＝9.0Hz,2H,CH 2),4.25(d,J＝8.5Hz,2H,CH 2),6.80(d,J＝8.0Hz,2H,Ar),6.91-6.93(m,2H,Ar),7.01-7.02(m,4H,Ar),7.09-7.10(m,2H,Ar),7.15-7.18(m,2H,Ar),7.25-7.36(m,4H,Ar),7.37(s,2H,Ar). 13C{1H}NMR(126MHz,CDCl 3)δ160.5(m),150.4(m),149.2(m),139.0,137.4,135.5(m),131.4(m),129.6(m),126.9(m),123.0,120.9,110.0,80.4,59.1(m),34.8(m),31.4(m). 31P{1H}NMR(202MHz,CDCl 3)δ-15.41(s).HRMS(ESI)calcd.for C 71H 95O 2P 2[M+H] +:1041.6807,Found:1041.6802,[α] 20 D＝+140.4(c＝0.5,丙酮).
实施例22：
催化剂Rh(6a)OAc 2的制备：
在N 2氛围下，向一个10mL单口瓶中加入[RuPhCl 2] 2(25mg,0.05mmol)、配体6a(61mg,0.103mmol),然后加入2mLDMF。100℃条件下反应3h。冷却至室温，然后加入1.5mL无水醋酸钠(0.111g,1.3mmol)的甲醇溶液。20Min后加入脱氧的去离子水。有灰色固体从反应体系中析出，过滤，减压除去溶剂和水就可以得到催化剂Rh(6a)OAc 2(57mg,产率＝71％)。
实施例23：
催化剂Rh(6a)(CF 3CO) 2的制备：
在N 2氛围下，向一个10mL单口瓶中加入双-(2-甲基烯丙基)环辛-1,5-二烯钌(32mg,0.05mmol)、配体6a(61mg,0.103mmol),然后加入2mL丙酮。40℃条件下反应0.5h。然后加入三氟乙酸(33mg,0.3mmol),40℃条件下搅拌过夜，减压除去溶剂，然后加入1mL石油醚，过滤得到目标产物Rh(6a)(CF 3CO) 2(81mg,产率＝88％)。
实施例24：
配体6a在2-甲基肉桂酸的不对称氢化中的应用：
在N 2氛围下，向氢化小瓶中加入2-甲基肉桂酸(162mg,1mmol)、催化剂Rh(6a)OAc 2(0.8mg,0.001mmol)以及1mL的甲醇。在10atm的氢气氛围下进行12h后，原料全部转化为产物。将产物和苯胺进行缩合生成酰胺，来测量产物的对映选择性(ee>99％)。HPLC条件：DaicelADH,进样量2μL(c＝1mg/mL),IPA/hexane＝90/10,1.0mL/Min,210nm,t R(major)＝26.8Min,t R(minor)＝29.7Min。
采用6a应用于多种物质的转化率参见图1所示。
以上内容是结合具体的优选实施方式对本发明所作的进一步详细说明，不能认定本发明的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干简单推演或替换，都应当视为属于本发明的保护范围。

Claims (10)

  1. 一种氧杂螺环双磷配体，其特征在于，具有以下通式(I)的结构：
    Figure PCTCN2018075860-appb-100001
    通式(I)中：
    R 1、R 2独立为烷基、烷氧基、芳基、芳氧基或者氢原子，R 1、R 2、R 3和R 4可成环或不成环；R 5、R 6独立为烷基、芳基或者氢原子；R 7、R 8为烷基、苄基或者芳基。
  2. 根据权利要求1所述的化合物，其特征在于，所述氧杂螺环双磷配体是(±)-氧杂螺环双膦配体，(+)-氧杂螺环双膦配体，或(-)-氧杂螺环双膦配体。
  3. 根据权利要求1所述的化合物，其特征在于，所述氧杂螺环双磷配体是下式化合物：
    Figure PCTCN2018075860-appb-100002
    其中，Ar为烷基、苄基或者芳基。
  4. 根据权利要求3所述的化合物，其特征在于，其中Ar为苯基、烷基或者烷氧基取代的苯基。
  5. 一种合成权利要求3-4任一项所述的化合物的方法，其特征在于，通过以下的路线合成得到：
    Figure PCTCN2018075860-appb-100003
  6. 权利要求1-5任一项所述的化合物在催化不对称反应中的应用，其特征在于，所述不对称反应包括：氢化反应，氢甲酰化反应，硅氢化反应，硼氢化反应，氢羟基化反应，氢氨化反应，氢氰基化反应，异构化甲酰基化反应，氢氨甲基化反应，转移氢化反应，烯丙基化反应，烯烃复分解反应，环异构化反应，Diels-Alder反应，不对称偶联反应，Aldol反应，Michael加成反应，不对称环氧化反应，动力学拆分和[m+n]环化反应。
  7. 根据权利要求6所述的应用，其特征在于，该化合物制成的双膦醋酸钌络合物在有机溶剂中对不饱和羧酸的氢化具有很高的活性和对映选择性，大于99％。
  8. 根据权利要求6所述的应用，其特征在于，所述双膦醋酸钌络合物是下式化合物：
    Figure PCTCN2018075860-appb-100004
    其中，R＝烷基，氟代烷基或芳基。
  9. 一种催化不对称反应，其特征在于，使用权利要求1-5任一项所述的化合物作为催化剂，反应路线如下：
    Figure PCTCN2018075860-appb-100005
    其中，R＝烷基，氟代烷基或芳基。
  10. 一种双膦醋酸钌络合物，其特征在于，所述双膦醋酸钌络合物是下式化合物：
    Figure PCTCN2018075860-appb-100006
    其中，R＝烷基，氟代烷基或芳基。
PCT/CN2018/075860 2018-02-08 2018-02-08 氧杂螺环双膦配体的合成与应用 WO2019153203A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CN2018/075860 WO2019153203A1 (zh) 2018-02-08 2018-02-08 氧杂螺环双膦配体的合成与应用
EP18904663.4A EP3730502B1 (en) 2018-02-08 2018-02-08 Synthesis and application of oxaspirocyclodiphosphine ligand
US16/770,087 US11299507B2 (en) 2018-02-08 2018-02-08 Synthesis and use of oxa-spirodiphosphine ligand

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/075860 WO2019153203A1 (zh) 2018-02-08 2018-02-08 氧杂螺环双膦配体的合成与应用

Publications (1)

Publication Number Publication Date
WO2019153203A1 true WO2019153203A1 (zh) 2019-08-15

Family

ID=67548677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/075860 WO2019153203A1 (zh) 2018-02-08 2018-02-08 氧杂螺环双膦配体的合成与应用

Country Status (3)

Country Link
US (1) US11299507B2 (zh)
EP (1) EP3730502B1 (zh)
WO (1) WO2019153203A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724781A (zh) * 2021-08-30 2023-03-03 凯特立斯（深圳）科技有限公司 一种合成乌帕替尼关键手性中间体的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071444B2 (en) * 2020-06-05 2024-08-27 Shenzhen Catalys Technology Co., Ltd Synthesis and use of oxa-spirodiphosphine ligand
CN115304617A (zh) * 2021-05-08 2022-11-08 惠州凯特立斯科技有限公司 一种大位阻氧杂螺环二酚及其双膦配体的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439643A (zh) * 2003-02-21 2003-09-03 南开大学 螺环双膦配体
CN1562926A (zh) * 2004-04-14 2005-01-12 南开大学 新型螺环双膦配体及其在不对称催化氢化中的应用
JP2010053049A (ja) * 2008-08-26 2010-03-11 Chiba Univ ジホスフィン化合物、その遷移金属錯体およびその遷移金属錯体を含む触媒並びにホスフィンオキシド化合物及びジホスフィンオキシド化合物
WO2017135897A1 (en) * 2016-02-02 2017-08-10 Agency For Science, Technology And Research A catalyst for the carbonylation of alkenes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210340168A1 (en) * 2020-04-30 2021-11-04 Shenzhen Catalys Technology Co., Ltd. OXA-SPIRODIPHOSPHINE LIGAND AND METHOD FOR ASYMMETRIC HYDROGENATION OF alpha, beta-UNSATURATED CARBOXYLIC ACIDS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1439643A (zh) * 2003-02-21 2003-09-03 南开大学 螺环双膦配体
CN1562926A (zh) * 2004-04-14 2005-01-12 南开大学 新型螺环双膦配体及其在不对称催化氢化中的应用
JP2010053049A (ja) * 2008-08-26 2010-03-11 Chiba Univ ジホスフィン化合物、その遷移金属錯体およびその遷移金属錯体を含む触媒並びにホスフィンオキシド化合物及びジホスフィンオキシド化合物
WO2017135897A1 (en) * 2016-02-02 2017-08-10 Agency For Science, Technology And Research A catalyst for the carbonylation of alkenes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3730502A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724781A (zh) * 2021-08-30 2023-03-03 凯特立斯（深圳）科技有限公司 一种合成乌帕替尼关键手性中间体的方法
WO2023029236A1 (zh) * 2021-08-30 2023-03-09 凯特立斯（深圳）科技有限公司 一种合成乌帕替尼关键手性中间体的方法

Also Published As

Publication number Publication date
EP3730502B1 (en) 2024-10-02
US11299507B2 (en) 2022-04-12
EP3730502A1 (en) 2020-10-28
EP3730502A4 (en) 2021-02-24
US20200308206A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
CN110128471B (zh) 氧杂螺环双膦配体的合成与应用
US6855657B2 (en) Ortho substituted chiral phosphines and phosphinites and their use in asymmetric catalytic reactions
US7105702B2 (en) P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
Schwink et al. New C2-symmetrical ferrocenyl diamines as ligands for ruthenium catalyzed transfer hydrogenation
WO2019153203A1 (zh) 氧杂螺环双膦配体的合成与应用
US7589218B2 (en) Chiral spiro compounds and their use in asymmetric catalytic reactions
Zhong et al. New β-amino alcohols with a bicyclo [3.3. 0] octane scaffold in an asymmetric Henry reaction
JP4837857B2 (ja) キラル配位子、その遷移金属錯体および不斉反応におけるその使用
Asami et al. Enantioselective addition of dialkylzinc to aldehydes catalyzed by (S)-2-(N, N-disubstituted aminomethyl) indoline
WO2019113874A1 (zh) 基于四甲基螺二氢茚骨架的膦配体化合物及其中间体和制备方法与用途
US7169953B2 (en) P-chiral phospholanes and phosphocyclic compounds and their use in asymmetric catalytic reactions
US6380392B1 (en) Ligands based on chiral 2-amino-2′-hydroxy-1,1′-binaphthyl and related frameworks for asymmetric catalysis
CN110128472B (zh) 一种氧杂螺环pnn类型配体的合成与应用
US12071444B2 (en) Synthesis and use of oxa-spirodiphosphine ligand
Wen et al. Asymmetric pinacol coupling reaction catalyzed by dipeptide-type Schiff bases
CN114516814B (zh) 一种手性季碳α-氨基酸酯类化合物的催化不对称制备方法
EP2621893A1 (en) Process for the preparation of amino acid derivatives
JPH02190A (ja) 光学活性ホスフィン化合物
US20050014633A1 (en) Biphenyldiphosphine compounds
Aboulaala et al. Synthesis and evaluation of a range of enantiopure β-aminoalcohols derived from tartaric acid for asymmetric hydrogen transfer reduction of prochiral ketones
JP4795559B2 (ja) ｌ−メントールの製造方法
JP2855221B2 (ja) 光学活性３，４―ビスホスフィノピロリジン化合物
JP4213435B2 (ja) 光学活性アミン誘導体の製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18904663

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018904663

Country of ref document: EP

Effective date: 20200723

NENP Non-entry into the national phase

Ref country code: DE